Join
Live feed
·
PRReleasevia Quantisnow
Entrada Therapeutics Inc. logo

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

ByQuantisnow·Wall Street's wire, on your screen.
TRDA· Entrada Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TRDA (Entrada Therapeutics Inc.) and more on Quantisnow.